Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline-resectable oesophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001).
- DOI
- 10.1002/ctm2.70691
- Published
- 2026 May
- Container
- Clinical and translational medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ctm2.70691,
title = {Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline-resectable oesophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001).},
author = {Wu JD and Wang DS and Wang ZQ and Li QQ and Xu BY and Ren C and Fang CY and Huang Y and Li ZC and Chen JY and Tan Q and Li YH and Yang H},
year = {2026},
journal = {Clinical and translational medicine},
doi = {10.1002/ctm2.70691},
url = {https://doi.org/10.1002/ctm2.70691}
}RIS
TY - JOUR TI - Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline-resectable oesophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001). AU - Wu JD AU - Wang DS AU - Wang ZQ AU - Li QQ AU - Xu BY AU - Ren C AU - Fang CY AU - Huang Y AU - Li ZC AU - Chen JY AU - Tan Q AU - Li YH AU - Yang H PY - 2026 JO - Clinical and translational medicine DO - 10.1002/ctm2.70691 UR - https://doi.org/10.1002/ctm2.70691 ER -
APA
JD, W., DS, W., ZQ, W., QQ, L., BY, X., C, R., CY, F., Y, H., ZC, L., JY, C., Q, T., YH, L., & H, Y. (2026). Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline-resectable oesophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001).. Clinical and translational medicine. https://doi.org/10.1002/ctm2.70691
Source records
- pubmed · retrieved 2026-09-25T07:57:35.913Z